Condition
Myasthenia Gravis Crisis
Total Trials
5
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 4 (2)
Trial Status
Recruiting3
Not Yet Recruiting1
Unknown1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06860633Phase 4RecruitingPrimary
Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod
NCT06688253Phase 4Not Yet RecruitingPrimary
Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis
NCT06617741Recruiting
Myasthenia Gravis Foundation of America Global MG Patient Registry
NCT05214612Recruiting
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
NCT04674605Unknown
A Prospective Cohort Study Of Myasthenia Gravis
Showing all 5 trials